Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) — Cash Flow-to-Debt Ratio
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (600671) has a Cash Flow-to-Debt Ratio of -0.06x as of September 2025, meaning its operating cash flow of CN¥-19.96 Million could theoretically repay 0% of its total liabilities (CN¥335.43 Million) in one year. See how much free cash does Hangzhou TianMuShan Pharmaceutical Enter generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd Cash Flow-to-Debt Ratio (1998–2024)
Historical debt coverage capacity for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd across 27 annual periods. Also explore net asset growth rate of Hangzhou TianMuShan Pharmaceutical Enter to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd (1998–2024)
Year-by-year debt coverage analysis for Hangzhou TianMuShan Pharmaceutical Enterprise Co Ltd. For market capitalisation and broader financial context, see 600671 company net worth.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.10x | CN¥-36.67 Million | CN¥356.44 Million | ▼ -46.2% |
| 2023 | -0.07x | CN¥-20.43 Million | CN¥290.34 Million | ▼ -7.3% |
| 2022 | -0.07x | CN¥-19.37 Million | CN¥295.36 Million | ▲ +16.1% |
| 2021 | -0.08x | CN¥-26.42 Million | CN¥338.09 Million | ▼ -225.0% |
| 2020 | -0.02x | CN¥-8.40 Million | CN¥349.18 Million | ▼ -105.9% |
| 2019 | 0.41x | CN¥161.13 Million | CN¥393.60 Million | ▲ +131.0% |
| 2018 | 0.18x | CN¥70.71 Million | CN¥398.99 Million | ▲ +156.0% |
| 2017 | 0.07x | CN¥24.52 Million | CN¥354.18 Million | ▲ +934.1% |
| 2016 | 0.01x | CN¥1.61 Million | CN¥240.01 Million | ▲ +199.4% |
| 2015 | -0.01x | CN¥-1.47 Million | CN¥217.63 Million | ▼ -306.5% |
| 2014 | 0.00x | CN¥653.79K | CN¥200.40 Million | ▼ -93.9% |
| 2013 | 0.05x | CN¥12.37 Million | CN¥230.01 Million | ▲ +155.1% |
| 2012 | -0.10x | CN¥-19.82 Million | CN¥203.17 Million | ▼ -163.0% |
| 2011 | -0.04x | CN¥-6.49 Million | CN¥175.00 Million | ▲ +51.2% |
| 2010 | -0.08x | CN¥-12.60 Million | CN¥165.66 Million | ▼ -240.9% |
| 2009 | 0.05x | CN¥7.58 Million | CN¥140.53 Million | ▼ -67.2% |
| 2008 | 0.16x | CN¥21.19 Million | CN¥128.78 Million | ▼ -54.6% |
| 2007 | 0.36x | CN¥47.53 Million | CN¥131.16 Million | ▼ -24.1% |
| 2006 | 0.48x | CN¥55.39 Million | CN¥116.04 Million | ▲ +650.2% |
| 2005 | 0.06x | CN¥8.48 Million | CN¥133.32 Million | ▲ +395.6% |
| 2004 | 0.01x | CN¥1.35 Million | CN¥105.49 Million | ▲ +103.2% |
| 2003 | -0.40x | CN¥-41.13 Million | CN¥103.88 Million | ▼ -318.6% |
| 2002 | 0.18x | CN¥21.80 Million | CN¥120.32 Million | ▲ +170.6% |
| 2001 | 0.07x | CN¥10.52 Million | CN¥157.11 Million | ▲ +207.0% |
| 2000 | -0.06x | CN¥-9.67 Million | CN¥154.60 Million | ▼ -112.2% |
| 1999 | 0.51x | CN¥49.09 Million | CN¥95.68 Million | ▲ +1800.8% |
| 1998 | 0.03x | CN¥2.36 Million | CN¥87.30 Million | — |